AOD-9604 Dosage Guide: Protocols & Charts [2026]

Master AOD-9604 dosing with comprehensive protocols, injection schedules, cycling strategies, and body-weight adjusted dosage charts. Learn optimal timing, administration technique, and how to structure your AOD-9604 cycle for maximum fat loss results.

Understanding AOD-9604 & Its Dosing Basis

AOD-9604 is a modified fragment of human growth hormone, specifically the C-terminal fragment 176-191. This peptide was developed by Metabolic Pharmaceuticals in Australia and represents a breakthrough in targeted fat loss because it carries the lipolytic (fat-burning) properties of hGH without the anabolic effects that could trigger unwanted side effects like joint pain, carpal tunnel, or blood sugar dysregulation.

The dosing of AOD-9604 is based on its unique mechanism of action: it works directly on fat cells to increase fatty acid oxidation while simultaneously inhibiting new fat cell formation (lipogenesis). Unlike full growth hormone, which must be dosed higher and carries systemic effects, AOD-9604 achieves its fat-loss effects at much lower doses—typically in the 250-500 microgram range daily—making it both cost-effective and side-effect-favorable compared to hGH.

Understanding this distinction is crucial because it means AOD-9604 doesn't require the careful monitoring of growth hormone axis suppression that traditional hGH therapy demands. You can use straightforward protocols without IGF-1 monitoring or complex cycling considerations tied to HPA axis recovery. The dosing is more linear: higher doses generally produce stronger fat loss effects up to a plateau around 500 mcg daily.

Starting Dosage: The Conservative Approach

The conservative starting dose for AOD-9604 is 250 micrograms (0.25 mg) injected once daily via subcutaneous injection. This dose allows you to assess your individual tolerance, gauge injection site reactions, and establish baseline metabolism before increasing to therapeutic levels. Starting conservatively is essential even though AOD-9604 is well-tolerated overall.

At 250 mcg daily, you'll typically notice initial metabolic effects within 3-5 days: increased energy, slightly elevated body temperature, and early signs of appetite modulation. Many beginners report that their normal appetite simply decreases—they eat less without conscious restriction. This is the peptide beginning to signal satiety centers in the hypothalamus, indicating that the dose is active systemically.

After 1-2 weeks at 250 mcg, assuming no adverse reactions beyond minor injection site inflammation or mild headache, most users advance to 300 mcg daily. This step-wise titration ensures you find your personal tolerance window and optimal dose without overshooting into unnecessarily high doses. For individuals under 160 pounds or with sensitivity to peptides, remaining at 250-300 mcg for the full 12-week cycle may produce excellent results.

Standard Dosing Protocols & Schedules

The gold-standard protocol for AOD-9604 is once-daily injection at 300-500 mcg, administered every morning in a fasted state. This protocol balances efficacy, convenience, and side effect minimization. Most clinical research supporting AOD-9604's fat-loss benefits used once-daily dosing in the 300-500 mcg range, making this the most evidence-based approach.

A typical beginner protocol looks like: Week 1-2 at 250 mcg daily, Week 3-12 at 300-400 mcg daily, then 4 weeks off. An intermediate protocol escalates more aggressively: Week 1-2 at 250 mcg, Week 3-4 at 350 mcg, Week 5-12 at 500 mcg daily, then 4-6 weeks off. The advanced protocol for experienced users may involve 16 weeks at 400-500 mcg with 6 weeks off, or pulse dosing where users do 3 weeks on, 1 week at a reduced dose, then resume full dosing—this approach maintains receptivity longer.

Some experienced users employ a "high-low" protocol: alternating between 300 mcg and 500 mcg every other day. This approach theoretically maintains receptor sensitivity while reducing overall peptide consumption, though research doesn't confirm it's superior to consistent daily dosing. The simplest and most effective approach for most people remains consistent once-daily dosing at a fixed dose.

Injection Timing & Administration

AOD-9604 should be injected every morning immediately upon waking, before food consumption, ideally 30-60 minutes before breakfast. This timing capitalizes on your fasted metabolic state—insulin is low, glucagon is elevated, and your body is naturally primed for fat oxidation. Injecting while fasted amplifies the synergistic effect between AOD-9604's lipolytic signaling and your body's natural morning fat-burning physiology.

The mechanics of timing matter because AOD-9604 works systemically within minutes of injection. When you're fasted, the peptide has maximum impact on adipose tissue lipolysis without competing with dietary amino acids or glucose for cellular uptake. If you eat immediately after injection, the peptide still works, but the effect is blunted because your insulin response and nutrient absorption shift the metabolic state away from pure fat oxidation.

Evening or afternoon injections are not ideal because you're moving into a fed state, exercise is typically finished, and your body is preparing for sleep—a period of lower metabolic rate. Some users report successfully using AOD-9604 pre-workout (morning or afternoon), which can enhance fat mobilization during exercise, but the classic morning-fasted approach remains the gold standard supported by user experience and pharmacology.

Subcutaneous Injection Technique

AOD-9604 is always administered via subcutaneous (sub-Q) injection, never intravenously or intramuscularly. Subcutaneous injection means inserting the needle into the fatty tissue layer just beneath the skin, not into muscle. This route ensures consistent absorption kinetics and is the safest method for peptide administration in non-clinical settings.

To inject properly: gather supplies (insulin syringe with 28-30 gauge needle, alcohol swab, sharps container), reconstitute your AOD-9604 powder with bacteriostatic water according to the concentration provided (usually mixed to 10 mcg/0.1 mL or 10 mcg/0.01 mL), draw your dose into the syringe, and pinch a fold of skin and fat on your abdomen, love handles, or thighs. Insert the needle at a 45-90 degree angle into the pinched fold, inject slowly, wait 3 seconds, then withdraw. Rotate injection sites daily to prevent lipohypertrophy (fatty tissue buildup at injection sites).

Common subcutaneous injection sites include the lower abdomen, flanks, upper thighs, and back of upper arms. Never inject into areas with active inflammation, bruising, or scar tissue. Allow at least one inch between injection sites if injecting daily in the same general area. Use a fresh needle every time—never reuse needles as they dull quickly and increase tissue trauma. Proper technique minimizes injection site reactions, bruising, and ensures predictable peptide absorption.

Cycling Strategies: On & Off Periods

The standard cycling strategy for AOD-9604 is 12 weeks on, 4 weeks off. This approach provides adequate time for fat loss (3 months of continuous exposure) while allowing 1 month for receptor reset and metabolic homeostasis. The 12-week on-period aligns with typical research timeframes for measuring body composition changes, and users consistently report that most significant fat loss occurs in weeks 4-12.

During your 4-week off-period, your body normalizes sensitivity to AOD-9604's signaling pathways and clears any residual peptide from receptor sites. Your appetite regulation returns to baseline, and hormonal axes reset. Importantly, the fat loss achieved during the 12-week cycle is largely maintained during the off-period if you continue your diet and exercise habits—AOD-9604 provides an advantage during the cycle, but the underlying lifestyle changes support permanence.

More aggressive protocols extend the on-period to 16 weeks with 6 weeks off, or implement pulse-dosing where users follow 3 weeks on at full dose, 1 week at half-dose (e.g., 250 mcg instead of 500), then resume full dosing for another 3 weeks. The pulse approach theoretically maintains receptor sensitivity over extended use, though empirical evidence suggests the standard 12-on/4-off protocol works exceptionally well for most users. Multiple consecutive cycles (one after another) are possible—many users run 2-3 consecutive 12-week cycles annually during cutting phases.

Dosage Charts by Body Weight

AOD-9604 dosing can be roughly calculated by body weight, though individual variation is significant. A general guideline is approximately 2-3 micrograms per pound of body weight. Below are recommended dosing ranges by weight category for a standard 12-week cycle:

Under 140 lbs (BMI fit, athletic, or smaller frame): Start 200-250 mcg daily, progress to 250-300 mcg by week 3. This lower range avoids over-dosing in individuals who may be more sensitive to peptides or have less total body mass to lose.

140-180 lbs (Average adult): Start 250-300 mcg daily, progress to 300-400 mcg by week 3. This is the most common range and suits the majority of users seeking fat loss without muscle preservation concerns.

180-220 lbs (Larger frame, more body mass): Start 300 mcg daily, progress to 400-500 mcg by week 3. Heavier individuals typically benefit from higher doses because they have more adipose tissue and higher baseline metabolic needs.

Over 220 lbs (Obese or very muscular): Start 350 mcg, progress to 500 mcg by week 3. Individuals with significant obesity may tolerate and require higher doses, and muscular individuals at high body weight can handle higher peptide concentrations without adverse effects.

Remember: these are guidelines, not absolute rules. Individual pharmacokinetics vary based on genetics, metabolism, kidney function, and prior peptide exposure. Always start lower and titrate up rather than starting at the high end of your weight range.

Advanced Protocols & Stacking

Advanced users often combine AOD-9604 with other peptides or compounds to enhance results or target multiple goals simultaneously. AOD-9604 stacks particularly well with CJC-1295/GHRP-6 because the latter increase endogenous growth hormone production, while AOD-9604 provides direct fat-loss signaling. A typical stack might involve CJC-1295 100 mcg + GHRP-6 100 mcg twice daily (morning and evening) combined with AOD-9604 300-500 mcg once daily in the morning. This approach targets fat loss plus GH-mediated recovery and muscle preservation.

Another popular stack combines AOD-9604 with Ipamorelin, which is a gentler GH secretagogue with fewer side effects than GHRP-6. The dosing would be Ipamorelin 200-300 mcg twice daily plus AOD-9604 300-500 mcg daily. This combination is particularly popular with users who want fat loss and improved body composition without the intensity of full GH-releasing peptides.

For pure fat-loss stacking, some advanced users combine AOD-9604 with Tesamorelin, which is a synthetic GHRH that increases visceral fat loss. However, this combination is rarely necessary—AOD-9604 alone achieves significant fat loss for most users. The practical recommendation: master AOD-9604 alone first, then add complementary peptides only if targeting specific secondary goals like recovery or muscle preservation. Most users find that AOD-9604 300-500 mcg daily, combined with proper diet and exercise, exceeds results from more complex stacking protocols.